The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
Millions of people worldwide are infected with the hepatitis C virus (HCV), for which the main current therapy is associated with severe side effects, limited efficacy, is contraindicated in many patients, and has issues of compliance. As a result, new HCV therapies that are more effective and better tolerated are required. This review describes the discovery of a new class of allosteric, non-nucleoside HCV polymerase inhibitors that demonstrate potential for the development of novel anti-HCV therapeutics.
Beaulieu
Pierre L
PL
Boehringer Ingelheim (Canada) Ltd, Research and Development, 2100 Cunard Street, Laval, QC H7S 2G5, Canada. pbeaulieu@lav.boehringer-imgelheim.com
D001562:Benzimidazoles / Q000627:therapeutic use; D001665:Binding Sites; D018360:Crystallography, X-Ray; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects / Q000201:enzymology*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D011487:Protein Conformation; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism
D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase